EP3092004A4
Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
Abstract
This record has no abstract on file.
Term
Projected expiry 6 January 2035.
- Priority
- Filed
- Published
- Today
- Projected expiry
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| WO2006121168A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| WO2008011344A2 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| WO2008085562A2 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| WO2008156712A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| US2013309250A1 | Cites | United States of America | Search report |
| WO2014127917A1 | Cites | World Intellectual Property Organization (WIPO) | Search report |
| DAVID A. HOKEY ET AL: "Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 38, no. 5, 1 May 2008 (2008-05-01), DE, pages 1435 - 1445, XP055306792, ISSN: 0014-2980, DOI: 10.1002/eji.200737857 | Non-patent | – | Search report |
| CAI G ET AL: "PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4<+> T cells", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 230, no. 2, 1 August 2004 (2004-08-01), pages 89 - 98, XP004676304, ISSN: 0008-8749, DOI: 10.1016/J.CELLIMM.2004.09.004 | Non-patent | – | Search report |
| LUIS J CRUZ ET AL: "Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells", NANOMEDICINE, FUTURE MEDICINE LTD., LONDON, GB, vol. 7, no. 10, 1 October 2012 (2012-10-01), pages 1591 - 1610, XP008179318, ISSN: 1743-5889, DOI: 10.2217/NNM.12.131 | Non-patent | – | Search report |
| BOT ADRIAN ET AL: "Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 1, 14 December 2010 (2010-12-14), pages 132, XP021088850, ISSN: 1479-5876, DOI: 10.1186/1479-5876-8-132 | Non-patent | – | Search report |
| HONG GUO: "hTERT-based therapy: A universal anticancer approach (Review)", ONCOLOGY REPORTS, vol. 28, 1 January 2012 (2012-01-01), pages 1945 - 1952, XP055211187, ISSN: 1021-335X, DOI: 10.3892/or.2012.2036 | Non-patent | – | Search report |
| ELIZABETH K. DUPERRET ET AL: "Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT", MOLECULAR THERAPY, vol. 26, no. 2, 1 February 2018 (2018-02-01), US, pages 435 - 445, XP055738427, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.11.010 | Non-patent | – | Examiner |
| See also references of WO 2015103602A1 | Non-patent | – | Examiner |
15 members in 5 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 201461924108P | United States of America | – | |
| 201461924108 | United States of America | P | |
| 2015010305 | United States of America | W |
Members15
| Document | Office | Kind | |
|---|---|---|---|
| CA2935375A1 | Canada | A1 | |
| CA3156357A1 | Canada | A1 | |
| WO2015103602A1 | World Intellectual Property Organization (WIPO) | A1 | |
| KR20160105452A | Republic of Korea | A | |
| EP3092004A1 | European Patent Office (EPO) | A1 | |
| US2017007693A1 | United States of America | A1 | |
| EP3092004A4This record | European Patent Office (EPO) | A4 | |
| US10835595B2 | United States of America | B2 | |
| US2021085779A1 | United States of America | A1 | |
| KR102395498B1 | Republic of Korea | B1 | |
| KR20220062143A | Republic of Korea | A | |
| EP4070818A2 | European Patent Office (EPO) | A2 | |
| EP4070818A3 | European Patent Office (EPO) | A3 | |
| CA2935375C | Canada | C | |
| KR20250061774A | Republic of Korea | A |
16 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Opt-out of the competence of the unified patent court (upc) registeredP01 | P01 | |
| Application withdrawnWithdrawn18W | 18W | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN WITHDRAWNSTAA | STAA | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA | STAA | |
| First examination report despatched17Q | 17Q | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA | STAA | |
| Request for extension of the european patent (deleted)DAX | DAX | |
| Supplementary search report drawn up and despatchedA4 | A4 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 3092004
- Application
- 157332875
Titles3
- German
- PD1- UND PDL1-ANTIKÖRPER UND IMPFSTOFFKOMBINATIONEN UND VERWENDUNG DAVON ZUR IMMUNTHERAPIE
- English
- PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY
- French
- ANTICORPS PD1 ET PDL1 ET COMBINAISONS DE VACCIN ET UTILISATION DE CELLES-CI POUR L'IMMUNOTHÉRAPIE
Classification
- CPC, 37
- A61K39/12
- A61K39/395
- A61K39/00
- C07K16/2827
- A61K2039/505
- A61K2039/55516
- C12N2710/20034
- A61P37/04
- Y02A50/30
- A61K39/001157
- A61K39/001188
- A61K39/0011
- A61K39/001156
- A61K39/001189
- A61K39/001153
- A61K39/001186
- C07K14/005
- A61K39/001193
- A61K39/245
- A61K39/21
- A61K39/29
- A61K39/145
- A61K39/015
- A61K2300/00
- A61K39/08
- A61K39/292
- A61K39/155
- C07K16/2818
- A61K2039/58
- A61K9/0009
- A61K39/0005
- A61K2039/53
- A61K2039/54
- A61K2039/545
- A61M2037/0007
- A61N1/327
- C12N7/00
- IPC, 4
- A61K39 395
- A61K39 12
- A61K39 00
- C07K16 28
Designated states2
- Contracting states, 1
- Türkiye
- Extension states, 1
- Montenegro